Skip to main content
INBP
OTC Life Sciences

Secures Extension of $4M Credit Line, Adds New $250k Equipment Facility

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$0.18
Mkt Cap
$5.581M
52W Low
$0.172
52W High
$0.42
52W Position info
4.4% above low
Off High info
57% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

INBP is trading near its 52-week low of $0.172 (4.4% above the low) on light trading volume (0.1× avg).

Summary

Integrated BioPharma secured an extension of its critical $4 million revolving credit line and established a new $250,000 equipment line of credit with PNC Bank, providing essential liquidity and operational funding for the micro-cap company.


Key Events · Financing and Capital Events · INBP

  • Revolving Credit Line Extended

    The existing $4,000,000 revolving line of credit with PNC Bank has been extended to April 14, 2027, providing critical liquidity for the company.

  • New Equipment Line of Credit

    A new Convertible Line of Credit Note (Daily SOFR) for up to $250,000 has been established with PNC Bank, specifically for the purchase of equipment and/or vehicles.

  • Replaced Matured Facility

    The new $250,000 equipment line replaces a previous $500,000 convertible equipment line of credit that had matured on April 15, 2025.

  • New Compliance Covenants

    The loan agreement now includes extensive new representations, warranties, and covenants related to International Trade Laws, Sanctions, Anti-Money Laundering Laws, and Anti-Corruption Laws.


Analysis · INBP · Life Sciences

This filing is highly important for Integrated BioPharma, a micro-cap company facing severe operational challenges and substantial net losses as reported in its recent 10-Q. The extension of the $4 million revolving line of credit, which represents a significant portion of its market capitalization, provides crucial liquidity and extends its financial runway until April 2027. While the new equipment line is smaller than the one it replaces, securing any new financing, especially when the stock is trading near 52-week lows, is a positive signal for the company's ability to continue operations and manage its immediate financial needs. The new compliance covenants are standard for such agreements.

At the time of this filing, INBP was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.17 to $0.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INBP - Latest Insights

INBP
Jul 02, 2026, 10:37 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1797
Real-time Price: $0.1797 info
Change: $0 (0%) info
Market Cap: $5.581M info
INBP
May 08, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.250
Real-time Price: $0.1797 info
Change: -$0.0703 (-28%) info
Market Cap: $5.581M info
INBP
Apr 17, 2026, 4:17 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.280622
Real-time Price: $0.1797 info
Change: -$0.100922 (-36%) info
Market Cap: $5.581M info
INBP
Apr 17, 2026, 3:48 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $0.280622
Real-time Price: $0.1797 info
Change: -$0.100922 (-36%) info
Market Cap: $5.581M info
INBP
Feb 18, 2026, 4:23 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2987
Real-time Price: $0.1797 info
Change: -$0.119 (-40%) info
Market Cap: $5.581M info
INBP
Feb 11, 2026, 4:24 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.300
Real-time Price: $0.1797 info
Change: -$0.1203 (-40%) info
Market Cap: $5.581M info